• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

UnitedHealth investors await details behind 2025 outlook after exec’s murder

by January 15, 2025
written by January 15, 2025

By Sriparna Roy and Amina Niasse

(Reuters) – Analysts and investors are awaiting details behind UnitedHealth Group (NYSE:UNH)’s 2025 outlook when it reports quarterly results on Thursday, after its investor day presentations were canceled last month by the murder of executive Brian Thompson outside the New York hotel where the meeting was set to take place.

The company in a press release on Dec. 3 said it was expecting a profit of $29.50 to $30 per share, which was in line with Wall Street expectations. 

The murder unleashed a social media storm of patient dissatisfaction and ire over the health insurance industry’s practices that raised questions about whether UnitedHealth would come under pressure to change how it operates.

“I think at one level people are just looking for them to express confidence in the outlook, and what are some of the puts and takes there of significance,” said UBS analyst AJ Rice.

“Hearing more about the two challenging areas – Medicare and Medicaid – will be important underpinnings for feeling confident about that outlook,” Rice added.

The health insurance industry has been grappling with high medical costs for over a year, particularly in government Medicare plans for older adults or those with disabilities as many people sought treatment delayed during the COVID-19 pandemic. 

The issue extended in 2024 to Medicaid, which serves people with low income, with plans experiencing higher usage than budgeted, said Morningstar analyst Julie Utterback.

As states re-determined eligibility for their Medicaid plans, healthier members fell off the rolls, leaving behind those who require more medical services.

“We expect the Medicaid mismatch in rates and utilization to constrain profit growth through most of 2025,” Utterback said.

Regulatory risks for the industry also may increase, with lawmakers focused on pharmacy benefit managers and their role in high drug costs. UnitedHealth’s Optum is one of the nation’s largest PBMs.

UnitedHealth will likely face questions about its business practices and the potential for regulatory or consumer backlash, said James Harlow, senior vice president at Novare Capital Management, which owns more than 46,000 UnitedHealth shares. 

“It’ll still be in the minds of folks that view these companies as villains, but all the companies can do is just continue to operate, beat numbers and continue to give cash back to shareholders,” Harlow said.

COST TRENDS

More broadly for insurers, the focus will remain on enrollment and cost trends, which will impact the 2025 outlook and the ability for each company to hit its margin targets, J.P. Morgan analyst Lisa Gill said in a note.

The expiration of enhanced tax credits that subsidize the cost of health plans for millions of Americans under the Affordable Care Act, popularly known as Obamacare, were extended through 2025 but could be at risk under President-elect Donald Trump, who takes office on Jan. 20.

Barclays (LON:BARC) analyst Andrew Mok sees a 50%-75% chance that the new administration will allow those credits to expire this year, leading to a 15% to 20% decrease in Obamacare insurance enrollment for 2026. Obamacare plans are sold through federal and state-based online exchanges.

“Medicare Advantage probably has a little more favorable backdrop when the Trump administration’s fully settled in. The question marks tend to be around the public exchanges and to a lesser degree around Medicaid,” said UBS’s Rice.

Analysts are estimating UnitedHealth will report a fourth-quarter profit of $6.72 per share and revenue of $101.76 billion on Thursday, according to LSEG data.

UnitedHealth shares have fallen 11% since Dec. 4, the day Thompson was killed, to about $543. They are up nearly 5% from a year ago. 

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Republican bill seeks to curtail US FTC’s merger-busting powers
next post
Bank of NY Mellon earnings beat by $0.03, revenue topped estimates

You may also like

BASF results down on impairments, restructuring

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • Trump holds off on Day 1 tariffs, but hints at duties for Canada, Mexico on Feb. 1
    • Earnings call: Anika Therapeutics Focuses on HA Products Amid Restructuring

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy